Generic Zepbound: is there one, and what stands in the way?

Is there a generic Zepbound or generic tirzepatide?

No. Drugs@FDA lists only two tirzepatide applications, both held by Eli Lilly: NDA 217806 (Zepbound) and NDA 215866 (Mounjaro), and a search for generic (ANDA) tirzepatide applications returns no approval.^[1][2][3]

• Mounjaro is not a generic Zepbound. It is the same molecule under a separate Lilly application, approved for type 2 diabetes; see Zepbound vs Mounjaro.^[3]
• Compounded tirzepatide is not a generic. The FDA says compounded drugs “are not FDA approved” and are not reviewed for safety, effectiveness or quality.^[11] See compounded tirzepatide.
• Generic name is not generic version. Tirzepatide is the generic (non-proprietary) name of the drug in Zepbound and Mounjaro; a “generic version” means an FDA-approved copy from another company, and none exists yet.^[10][1]
• An approved generic would be identical in active ingredient. It would be approved under an abbreviated application that relies on Zepbound as the reference drug, as the filings below do.^[6]

When will Zepbound be generic? The exclusivity dates

FDA exclusivity on tirzepatide ends between May 13, 2027 and December 19, 2028, depending on the product and use.^[4][5]

The new chemical entity date comes from the FDA rule that bars a generic application for the same active moiety “for a period of 5 years from the date of approval of the first approved NDA.”^[7] The first tirzepatide approval was Mounjaro, on May 13, 2022, so the 5 years end on May 13, 2027.^[3][5] The same rule lets an application be submitted after 4 years if it certifies that a patent is invalid or not infringed, which is why filings began on May 13, 2026.^[7][6]

Zepbound patent expiration dates

Zepbound's patents listed with the FDA expire between May 13, 2036 and July 22, 2039.^[4]

Tirzepatide patent expiration for Mounjaro

Mounjaro shares most of these patents and has one more, 12,295,987, which runs to December 30, 2041, so the last listed tirzepatide patent expires in 2041.^[5] Patent expiry is a ceiling, not a forecast: a generic maker that wins a patent challenge, or settles, can launch earlier, and the FDA list shows no such outcome yet.^[6]

Generic Zepbound applications already filed

Generic makers have filed applications for every Zepbound strength: the FDA's Paragraph IV list, as of October 27, 2026, shows up to 12 per autoinjector strength, all first submitted on May 13, 2026.^[6] A Paragraph IV filing certifies that a listed patent is invalid or will not be infringed.^[7]

The FDA does not name the companies on this list, and the 180-day first-filer exclusivity fields were blank.^[6] A filing is not an approval: as of November 2026 none of these applications has been approved.^[1]

Sandoz's filing and Lilly's lawsuits

One filer has identified itself, and Lilly has sued the generic makers.^[14][15]

• Sandoz, June 29, 2026: the FDA “has accepted for review two Abbreviated New Drug Applications (ANDAs) for generic versions of tirzepatide,” for an autoinjector covering the indications of both Mounjaro and Zepbound. Sandoz says its product could be among the first generics “subject to FDA approval.”^[14]
• Lilly, July and August 2026: Lilly reports that in July 2026 it “received notice that multiple generic companies had filed ANDAs,” and that in August 2026 it filed patent infringement actions against them in the U.S. District Court for the District of Delaware.^[15]
• Not public: Lilly's filing does not name the companies or give a trial date, and no court outcome had been reported as of November 2026.^[15]

Generic Zepbound timeline, 2022 to 2041

The dates that decide when a generic Zepbound can reach the market run from Mounjaro's approval in 2022 to the last listed patent in 2041.^{[3][2][4][5][6][14][15]}

1. May 13, 2022First tirzepatide approval (Mounjaro); the 5-year exclusivity clock starts.
2. November 8, 2023Zepbound approved for weight management.
3. May 13, 2026Four-year mark: first generic applications with patent challenges submitted.
4. June 29, 2026Sandoz says the FDA accepted two of its applications for review.
5. August 2026Lilly files patent suits against the generic makers in Delaware.
6. November 2026No generic approved.
7. May 13, 2027New chemical entity exclusivity ends for Zepbound and Mounjaro.
8. December 20, 2027Sleep apnea exclusivity ends for Zepbound.
9. December 19, 2028Last Mounjaro exclusivity (new patient population) ends.
10. May 13, 2036Compound patent 9,474,780 expires.
11. July 22, 2039Last listed Zepbound patent expires.
12. December 30, 2041Last listed Mounjaro patent expires.

A court ruling or settlement could move the generic launch earlier than the patent dates; nothing in this list predicts that outcome.

Generic Mounjaro: when will Mounjaro be generic?

There is no generic Mounjaro either, and its dates run later than Zepbound's: exclusivity on most Mounjaro products lasts to December 19, 2028 and its last listed patent to December 30, 2041.^[5][1]

Sandoz's filing covers both brands, and Lilly's suits cover generic versions of Mounjaro and/or Zepbound.^[14][15][6] The new patient population exclusivity ends three years after Mounjaro's December 19, 2025 approval for children aged 10 and older; how the two brands differ is on Zepbound vs Mounjaro.^[3]

Why it would be a generic, not a biosimilar

Tirzepatide is regulated as a drug, not a biologic, because it is a peptide of 40 or fewer amino acids. FDA rules define a protein as an amino acid polymer “greater than 40 amino acids in size,” and tirzepatide is a 39-amino-acid peptide.^[8][9] It was approved under new drug applications listed in the Orange Book, so copies go through the abbreviated (generic) pathway that the filings above use, not the biosimilar pathway.^[4][6]

What this means for the price today

With no generic approved, Zepbound's price is set by Lilly: self-pay prices on LillyDirect, checked November 13, 2026, run from $299 to $449 per four weekly doses with on-time refills.^[13] The worked prices are on Zepbound cost, and Medicare and Medicaid rules are on Zepbound insurance coverage. The FDA declared the tirzepatide shortage resolved on December 19, 2024.^[12]

Related

• Compounded vs ZepboundHow unapproved copies differ
• What is ZepboundThe approved drug and its uses
• Foundayo vs ZepboundLilly's lower-priced pill